DNLI
HealthcareDenali Therapeutics Inc. · Biotechnology · $3B
What is Denali Therapeutics Inc.?
Denali Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases, headquartered in South San Francisco, California.
Denali advances a pipeline of therapeutic candidates targeting conditions such as Parkinson's disease, ALS, Hunter syndrome, multiple sclerosis, and Alzheimer's disease. The company generates revenue primarily through collaboration agreements with partners including Biogen, Sanofi, and Takeda rather than from approved commercial products.
Denali Therapeutics was incorporated in 2013 and is based in South San Francisco, California.
- BIIB122/DNL151 — LRRK2 inhibitor in clinical trials for Parkinson's disease
- DNL310 — in Phase I/II trials for Hunter syndrome
- DNL343 — in Phase 1 trials for ALS
- SAR443122/DNL758 — in Phase II trials for cutaneous lupus erythematosus
Is DNLI a Good Stock to Buy?
UQS Score rates DNLI as Poor overall, reflecting broad weakness across most quality dimensions.
The Risk pillar stands out as the relative bright spot, suggesting the company maintains a manageable balance sheet profile compared to many clinical-stage peers.
Quality, Moat, and Growth all register as Weak, and Valuation is Elevated — a combination that warrants careful scrutiny from investors.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DNLI pay dividends?
No — Denali Therapeutics Inc. does not currently pay a dividend.
Denali Therapeutics does not pay a dividend. As a clinical-stage company with no approved products, capital is directed toward research, clinical trials, and pipeline development rather than shareholder distributions.
When does DNLI report earnings?
Denali Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
As a pre-revenue commercial company, quarterly results are largely shaped by collaboration milestone payments and operating expenses tied to clinical activity. Pipeline progress and partnership updates tend to drive more market reaction than traditional earnings metrics.
For the most recent quarter's results, visit Denali Therapeutics' investor relations page directly.
DNLI Price History
-68.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Denali Therapeutics Inc.?
Based on Denali Therapeutics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Denali Therapeutics do?
Denali Therapeutics discovers and develops treatments for neurodegenerative diseases including Parkinson's disease, ALS, Hunter syndrome, and Alzheimer's disease. The company operates through clinical-stage programs and collaboration agreements with major pharmaceutical partners.
Does DNLI pay dividends?
No, DNLI does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and development rather than returning cash to shareholders.
When does DNLI report earnings?
Denali Therapeutics reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is DNLI a good stock to buy?
The UQS Score rates DNLI as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. Investors should weigh these signals carefully alongside their own risk tolerance and research.
Is DNLI overvalued?
The UQS Valuation pillar for DNLI is rated Elevated, suggesting the current market price may not be well-supported by the company's fundamentals relative to peers. Full valuation metrics are available to Pro members.
What is DNLI's market cap bracket?
DNLI is classified as a mid-cap stock based on its current market capitalization.
Who founded Denali Therapeutics?
Denali Therapeutics was founded by a team of neuroscience-focused scientists and entrepreneurs. The company was formerly known as SPR Pharma Inc. and adopted its current name in March 2015. Founding details are widely available through public filings.
Is DNLI a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates DNLI as Poor. Clinical-stage companies carry inherent pipeline risk, and DNLI's Weak Moat and Growth scores suggest limited structural advantages at this stage. Pro members can view the complete analysis.
Unlock Full DNLI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare DNLI against sector peers on a standardized scoring framework
- ✓Get the complete analyst-grade view available to Pro members
Pro Analysis
DNLI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 15.2 | 0.0 | 19.0 | 0.6 | 69.1 | 0.0 | 0.0 |
| May 10, 2026 | 15.2 | 0.0 | 19.0 | 0.6 | 68.9 | 0.0 | +0.1 |
| May 9, 2026 | 15.1 | 0.0 | 19.0 | 0.0 | 68.9 | 0.0 | -0.6 |
| Apr 22, 2026 | 15.7 | 0.0 | 19.0 | 0.6 | 72.4 | 0.0 | -0.1 |
| Apr 2, 2026 | 15.8 | 0.0 | 19.0 | 0.8 | 72.4 | 0.0 | — |
DNLI — Pillar Breakdown
Quality
— 0.0/100 (25%)Denali Therapeutics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.6/100 (20%)Denali Therapeutics Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.1/100 (15%)Denali Therapeutics Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Denali Therapeutics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)Denali Therapeutics Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DNLI.
Score Composition
Financial Data
More Stock Analysis
How is the DNLI UQS Score Calculated?
The UQS (Unified Quality Score) for Denali Therapeutics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Denali Therapeutics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Denali Therapeutics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.